NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

231.1B

Vuru Grade

66.34/100

Current Price

$95.56
+0.52 (+0.55%)

Growth Price

$67.94
Overvalued by 28.90%

Stability Price

$24.72
Overvalued by 74.13%

Company Metrics

  • 21.84 P/E
  • 3.85 P/S
  • 3.22 P/B
  • 4.352 EPS
  • 13.46% Cash ROIC
  • 0.35 Cash Ratio
  • 2.719 / 2.86% Dividend
  • 1.38M Avg. Vol.
  • 2.42B Shares
  • 231.1B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Novartis' (NVS) Signifor Wins EU Approval For Rare Hormonal Disorder
Bidness ETC - Nov 24, 2014
Novartis AG (ADR) (NYSE:NVS) announced before US markets opened for trading Monday that the European Commission has approved its drug Signifor for the treatment of a rare hormonal disorder that is believed to affect about 1-2 in every 10,000 ...
Analysts Alert: Citi Trends, Inc. (NASDAQ:CTRN), Novartis AG (ADR) (NYSE ...
Stafford Daily - Nov 26, 2014
Novartis AG (ADR) (NYSE:NVS) was initiated with outperform rating coverage from analysts at Exane BNP Paribas which is being seen as a huge positive for the stock.
Novartis (NVS) Receives CHMP's Approval For Psoriasis Drug
Bidness ETC - Nov 21, 2014
Novartis AG (ADR) (NYSE:NVS) announced today that secukinumab has received positive feedback from the European Medical Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of moderate-to-severe plaque ...
Novartis AG Cosentyx May Face Pricing Pressures
Bidness ETC - Nov 24, 2014
The Committee for Medicinal Products for Human Use (CHMP), the European Commission's (EC) advisory body, issued a positive opinion for Novartis AG's (ADR) (NYSE:NVS) Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis.
Novartis AG (ADR) (NYSE:NVS) Updates On FDA Review Of LBH589
USMarketsDaily (blog) - Nov 25, 2014
Novartis AG (ADR) (NYSE:NVS) has offered an update on the progress of the review of its investigation drug for a condition known as multiple myeloma.
Novartis Posts Strong Third-Quarter Results; Cost-Cutting Efforts Pay Off
Bidness ETC - Oct 28, 2014
Novartis AG (ADR) (NVS) posted upbeat financial and operational results for the third quarter of its fiscal year (3QFY14) today before markets opened.
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
NASDAQ - Jul 25, 2014
Novartis reported third-quarter 2014 earnings per share of $1.33, up 48% from the year-ago period. Core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
Novartis AG (ADR) Boosts its Cancer Immunotherapy Presence
Motley Fool - Feb 18, 2014
Despite outstanding performance over the past year from biotech and pharma, you wouldn't be alone if you think they have more room to grow.
Novartis (NVS) to acquire start-up CoStim Pharmaceuticals in immunotherapy ... - Stockhouse
Novartis Releases Positive Phase 3 Results For Psoriatic Arthritis Drug
Bidness ETC - Sep 25, 2014
Novartis AG (ADR) (NVS) today released top line results for two late-stage pivotal studies, which evaluated its novel drug secukinumab as a treatment for psoriatic arthritis (PsA).
Novartis Announces Positive Phase-III Results For Secukinumab
Bidness ETC - Oct 23, 2014
Novartis AG (ADR) (NVS) announced today that its experimental drug AIN457 (Secukinumab) met its primary and secondary end points in two late-stage trials called MEASURE 1 and MEASURE-2.
Novartis' Secukinumab Receives Favorable FDA Panel Vote - Analyst Blog - Nasdaq